Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company facilities. The letter followed inspections of the company’s plants in San Diego and Mesa, Arizona. San Diego is where Dexcom’s headquarters is located, while the company last year decided to move manufacturing out of San Diego to […]
Dexcom
Data outlines need for CGM study design guidelines
A study looking at three leading continuous glucose monitors (CGMs), including systems from Abbott and Dexcom, signaled the need for new guidelines, investigators say. Published in the Journal of Diabetes Science and Technology, the study evaluated the latest-generation Abbott FreeStyle Libre 3, Dexcom G7 and Medtronic Simplera CGMs against different comparator methods and during clinically […]
Dexcom posts Q4 EPS miss, analysts remain high on coming catalysts
Dexcom (Nadsaq:DXCM) announced fourth-quarter results that came in mixed compared to the consensus forecast — but analysts are optimistic about 2025. Shares of DXCM initially fell after-hours yesterday on the after-market-close report — but by midday today, they were up more than 5% to $89.03 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported […]
Dexcom warns of missed G6 receiver alerts in Europe
Dexcom (Nasdaq:DXCM) recently issued an urgent field safety notice in Europe warning of a potential issue with certain G6 receivers. G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an issue in which alarms/alerts fail to function as designed. In rare instances, the alarm/alert may be missed or […]
Dexcom establishes direct presence in Italy with CGM launch, ends distro deal with Roche
Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to the country. The company plans to bring its continuous glucose monitoring (CGM) technology to Italy beginning in March 2025. This means it plans to end its distribution relationship with Roche next month. The companies plan to […]
Are over-the-counter CGMs on track to be one-hit wonders?
This medical device design expert’s family conducted a group trial of Dexcom Stelo and Abbott Lingo CGMs. By Steph Habif “Did you say you are now wearing a CGM?” my 78-year-old father asked me one day. “If so, what brand do you think is best for me to try?” My dad wanted my opinion because […]
Dexcom CEO says 2025 is ‘shaping up to be a good year’ with Stelo launch, GenAI integration
After a busy 2024, Dexcom (Nasdaq:DXCM) Chair and CEO Kevin Sayer believes the company is set for more milestones in 2025. In 2024, the company became the first to receive FDA approval for an over-the-counter (OTC) continuous glucose monitor (CGM), the Stelo device. Meanwhile, Dexcom continues to advance its G7 platform, its latest-generation CGM offering. […]
Dexcom inks glucose biosensor partnership with Life Time
Dexcom (Nasdaq:DXCM) announced that it entered into a new partnership with Life Time Inc., an operator of athletic country clubs. Life Time Inc., a “health and wellness pioneer,” has more than 170 athletic country clubs across the U.S. The chain of clubs also extends into Canada. In a post on LinkedIn, Dexcom said it announced […]
Dexcom expects sales to grow 14% in 2025
Dexcom (Nasdaq:DXCM) today announced preliminary financial results with projections for significant sales growth in 2025. Shares of DXCM dipped 1.5% to $76.57 in mid-morning trading today. The San Diego-based continuous glucose monitor (CGM) maker reported preliminary 2024 revenues of $4.032 billion. That marks an 11% increase over 2023. For 2025, Dexcom anticipates total revenue of […]
Abbott, Dexcom settle global CGM patent litigation
Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two leaders in the CGM space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing […]
